All Active Asset Capital (AAA) has been one of the year’s biggest stock risers, in a year where we have seen some massive gains especially in the small cap space. The shares reached fresh highs for 2020 at 8.5p via a 7% rise in the wake of news of a £11.5m placing at 8p to enable the tech investor to look for new tech opportunities in its chosen sector.
Power Metal Resources (POW) seems to rarely be out of the news, with the latest RNS from the company being that the metals exploration and development company has signed a drilling contract for an initial 500m of diamond drill programmed centred on the Victoria Vein at the Silver Peak project in British Columbia, Canada. Shares of Power Metal Resources celebrated with a 10% share price rise.
It goes without saying that management of listed companies are very much defined by share price performance, ideally, with the stock rising on their arrival at a company, and then to keep outperforming while they are at the wheel. However, in the case of waste plastic to hydrogen and energy group Powerhouse Energy (PHE), investors saluted the departure of former Chairman Cameron Davies from the board with a 10% share price rise leaving the stock at 2.77p.
Fast growing mining sector investor Gunsynd (GUN) was on the front foot with news regarding its latest investment. This consisted of paying C$250,000 / £146,000 into a precious metals royalty and streaming company Empress Royalty Corp. The company said that a highlight of the financing round in Empress was that it would give Gunsynd new commodity exposure to Silver, with the stock rising 5% as a result.
Equally fast growing pharma services group Open Orphan (ORPH) was back in demand, sporting an 8% share price rise. This came as investors noted the failure of BionVax’s Phase III universal flu vaccine, leaving Open Orphan’s rival product Imutex in the box seat as far as getting over the finish line. Some in the market mused that the apparent demise of BionVax could lead to a bidding war for Immutex from big pharma. Open Orphan acquired Imutex as part of its hVivo purchase at the turn of the year.
Sticking in the pharma area, and shares of Sensyne Health (SENS) added another 14%, after already tripling since August. The latest rally came in the wake of confirmation that the UK company had signed a research collaboration agreement with US giant Bristol Myers Squibb (BMY). The purpose of the agreement is to apply machine learning techniques to rare blood disease research.
Also in the pharma space, there was a return to form for Hemogenyx (HEMO) as traders did the math regarding how long it may be before Eli Lilly sign a license agreement with the UK listed biopharmaceutical group. The favoured timeframe is well before the end of next month. The stock of Hemogenyx squeezed up 12% to 10.9p.
Punters’ favourite / bears nemesis Eurasia Mining (EUA) twisted the knife again with an 8% rise, proving that the bullish momentum has still not left this situation, as the Russia focused palladium play continues its takeover process. Followers of the company were said to be waiting on fresh news on possible resource upgrades, as well as noting the first snow fall on the Southern Urals.
Disclaimer:
Zakmir.com is a purely journalistic website – Zak Mir is a member of the National Union of Journalists. There is no intention here of providing financial advice. It is recommended you seek an independent professional opinion before deciding whether or not to take any action with regard to anything written here.
